The world's first vaccine against dengue, developed by French drugmaker Sanofi, has shown the ability to protect against disease caused by three of four dengue virus strains in a keenly awaited clinical trial in Thailand.
Sanofi said on Wednesday the proof of efficacy was "a key milestone" in the 70-year quest to develop a viable dengue shot, adding the results also confirmed the safety profile of the vaccine candidate.
The mosquito-borne disease - also known as "breakbone fever" - is a threat to nearly 3 billion people and is caused by four different types of virus, none of which confers immunity from the others.
Sanofi's vaccine generated an antibody response for all four dengue virus types, but evidence of protection was only demonstrated against three of the four circulating in Thailand. Sanofi said researchers were carrying out analyses to understand the lack of protection for the fourth serotype.
The company's vaccine unit, Sanofi Pasteur, has already invested 350 million euros ($423 million) in a new French factory to make the three-dose vaccine and believes its product could generate 1 billion euros in yearly sales.
But uptake of the vaccine will depend on precisely how well doctors believe it can protect populations at risk in fast-expanding tropical cities from Rio to Manila, as well as travelers.
Sanofi gave no details on the level of protection in a brief statement. The full data are now being reviewed by scientific experts and public health officials, with detailed results to be published later this year.
Sanofi previously said it planned to present the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.
Large-scale late-stage Phase III clinical studies with 31,000 participants are under way with Sanofi's vaccine in 10 countries in Asia and Latin America.
Gene therapy for cystic fibrosis has for the first time shown slight but significant benefit on lung function, new British research reveals.
A new study has determined that soda drinks are responsible for more than 184,000 deaths with nearly 80% occurring in low to middle income countries
The plight of these urban areas show how dire the coming global freshwater shortage could get.
Coin-sized band analyzes blood glucose levels and releases insulin when needed
A WHO report has found that the use of lindane and DDT are linked to non-Hodgkin lymphoma
Pope Francis has said that the emissions trading is a ploy to allow wealthy emitters to continue their work
Russian sewerage dump is responsible for declining fish stock in the Baltic seas.
A new cancer drug will be tested as part of a joint effort by AstraZeneca and Lilly.
Smart technology and regulation will aid challenges in global power sector, helping to lower the carbon emitted globally.
A deal between the richest nations in the world has been seen as unlikely, as OECD seeks to phase out export credits.
Soon more than 1 billion consumers in developing nations will be able to buy their first air conditioner, increasing energy demand which will impact global warming
The European Union has given new authorization for 10 new types of genetically modified crops have been approved for a 10 year use for human consumption and animal feed.
Guinea's President Alpha Conde announced new emergency measures in Ebola fight on Saturday
'Meetings happened. Action didn’t,' says Medecins Sans Frontieres report.
WHO said that on many levels, the world is better prepared now than ever before for aflu pandemic
Myanmar health officals say an outbreak of H5N1 bird flu in Mandalay